Previous 10 | Next 10 |
home / stock / mmed:cc / mmed:cc news
In the recent years, we’ve seen more studies explore the therapeutic benefits of psychedelics, with researchers as well as public figures such as Prince Harry discussing the mental and physical health benefits of these substances. Some countries have even relaxed their laws on psychede...
A campaign that was working to legalize psychedelics in California has suspended its efforts to get a psychedelic legalization initiative on the 2024 ballot. Treat California is a citizen-driven ballot measure that would have funded the research and development of psychedelic medicines in Cal...
– Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated by the end of Q1 2024 – – MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 – ...
Supporters of a campaign to legalize psychedelics in Massachusetts believe they have gathered enough signatures to compel legislators to consider their initiative. If this is not successful, the group plans to put the psychedelics legalization measure on next year’s ballot. This move c...
A recent Canadian study has suggested that psilocybin, the main hallucinogenic agent in magic mushrooms, may ease the psychological distress associated with childhood trauma. Researchers say the psychedelic seemed to offer “particularly strong benefits” to individuals who faced ex...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, ...
– 53 participants enrolled across two sites – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...
Recent study findings published in the “Substance Use & Misuse” journal indicate that the use of psychedelics such as LSD is becoming especially prevalent among business managers in managerial positions. The study found that while there has been a general increase in psychedel...
Psychedelics are poised to transform the mental-health landscape in a way conventional mental-health treatments have failed to achieve. Recent research into the potential benefits and risks of psychedelics has uncovered significant evidence of their therapeutic effectiveness against a wide variet...
Governor Gavin Newsom of California has vetoed a measure that would legalize a number of psychedelics and establish a pathway for regulated access. In his message regarding the veto, the governor urged the legislature to present a new resolution in 2024 that created guidelines for regulated ac...
News, Short Squeeze, Breakout and More Instantly...
Hallucinogenic persistent perception disorder (HPPD) is an intoxication disorder caused by psychedelic drugs that encompasses a range of visual disturbances that occur in different time frames. The disorder also causes extreme anxiety as well as out-of-body sensations and is marked by shame as w...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the...
All Common shares will remain listed on Nasdaq Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today ...